NasdaqGM:FOLDBiotechs
Amicus Therapeutics (FOLD) Is Up 5.4% After Q3 Profit Return and Raised 2025 Revenue Outlook
Amicus Therapeutics recently reported a net income of US$17.31 million for the third quarter of 2025, marking a return to profitability compared to a net loss in the same period last year, and reaffirmed positive full-year guidance including projected total revenue growth of 15% to 22% for 2025.
This financial turnaround, marked by significant reduction in nine-month net losses and a continued forecast for positive GAAP net income, reflects new momentum in both the company's operations and...